FOUNDATIONONE®CDx

PATIENT
Huang, Cheng-Pin

TUMOR TYPE
Brain glioblastoma (GBM)
COUNTRY CODE
TW

REPORT DATE
10 Nov 2021
ORDERED TEST #
ORD-1227775-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Brain glioblastoma (GBM)
NAME Huang, Cheng-Pin
DATE OF BIRTH 02 January 1968
SEX Male
MEDICAL RECORD # 47743760

PHYSICIAN

ORDERING PHYSICIAN Hsu, Pin-Chuan
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN SITE Brain
SPECIMEN ID S110-30711 C (PF210345)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 15 October 2021
SPECIMEN RECEIVED 04 November 2021

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 3 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

NF1 loss exons 1-8
MDM2 amplification
PTEN Q171* - subclonal†
PPP2R2A rearrangement exon 8
RB1 loss exons 3-12
TERT promoter -146C>T

3 Disease relevant genes with no reportable alterations: ***EGFR, IDH1, PDGFRA***

† See About the Test in appendix for details.

2 Therapies with Clinical Benefit
0 Therapies with Resistance
23 Clinical Trials

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 3 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***NF1* -** loss exons 1-8	none	Selumetinib
10 Trials *see p. 11*		Trametinib
***MDM2* -** amplification	none	none
6 Trials *see p. 9*		
***PTEN* -** Q171* - subclonal	none	none
10 Trials *see p. 13*		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[6-8]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[6], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[9]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[6], in GBMs with a previous lower grade astrocytoma[7], and in giant cell GBM compared to classic GBM[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[10]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[10-12]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[13-15]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[10,12,14-15].

BIOMARKER

Tumor Mutational Burden

RESULT
3 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[16-18], anti-PD-1 therapies[16-19], and combination nivolumab and ipilimumab[20-25]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[16,26-27]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[28-29] or anti-PD-L1[30] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)[31]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[32-33]. Increased TMB has been reported to correlate with higher tumor grade in glioma[34] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[28], as well as with shorter OS of patients with diffuse glioma[35].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[16,26-30].

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
NF1

ALTERATION
loss exons 1-8

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in neurofibromatosis Type 1-associated neurofibroma[47-50], glioma or glioblastoma[50-54], and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus, based on limited clinical data[56-58] and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)[59-60]. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1-deficient MPNST[61]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[62], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[63].

FREQUENCY & PROGNOSIS

NF1 mutation has been observed in 5-6% of lower grade gliomas and 9-14% of glioblastoma multiforme (GBM) cases; homozygous deletion of NF1 was observed in 1% of lower grade gliomas and 2-3% of GBMs[40,64-66]. Among GBM subtypes, NF1 mutation and loss were reported most frequently in the mesenchymal subtype, 37% (14/28) and 38% (21/55) of cases, respectively[67]. NF1 loss was significantly associated with decreased overall and disease-specific survival in patients with lower grade gliomas (II-III), but not in those with GBM[68].

FINDING SUMMARY

NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key negative regulator of the RAS signaling pathway[69]. Neurofibromin acts as a tumor suppressor by repressing RAS signaling[70]. Alterations such as seen here may disrupt NF1 function or expression[70-79].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms[80-82]. Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000[83-84], and in the appropriate clinical context, germline testing of NF1 is recommended.

GENE
MDM2

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

MDM2 antagonists disrupt the MDM2-p53 interaction, thereby stabilizing p53[85]. Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents[86-87]. Preliminary Phase 1 studies of the MDM2-p53 antagonist alrizomadlin (APG-115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%–38% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors[88-89] . A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non-small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively[90]. Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti-leukemic response rates of 33% (25/75) and 37% (11/30), respectively[91-92] ; clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera[93]. The dual MDM2/MDM4 inhibitor ALRN-6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T-cell lymphoma in a Phase 2 study[94]; responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma[95-96] .

FREQUENCY & PROGNOSIS

In the Glioblastoma Multiforme (GBM) TCGA dataset, amplification of MDM2 has been found in 8% of cases[65]. A study has reported amplification of the 12q14-15 region, where MDM2 and CDK4 reside, in 5% (2/42) of GBMs[97]. Amplification of MDM2 has been associated with poor survival in patients with glioblastoma[97-98].

FINDING SUMMARY

MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins[99-101]. MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic[102-103]. Overexpression or amplification of MDM2 is frequent in cancer[104]. Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time-to-treatment failure on anti-PD-1/PD-L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification[105] and 2/3 patients with MDM2 or MDM4 amplification[106] experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression-free survival (PFS) in a retrospective analysis of non-small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)[107]. The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification[107].

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
PTEN

ALTERATION
Q171* - subclonal

TRANSCRIPT ID
NM_000314

CODING SEQUENCE EFFECT
511C>T

VARIANT ALLELE FREQUENCY (% VAF)
3.7%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[108-111]. Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus[112-114]. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[115-119], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[120], ovarian cancer[121], uterine leiomyosarcoma[122], and endometrial cancer[119] treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[123-124].

— Potential Resistance —

Limited clinical evidence in glioblastoma[26], leiomyosarcoma[125], and melanoma[126] suggests that PTEN alterations may predict a lack of response to anti-PD-1 therapy. In an analysis of 39 patients with metastatic melanoma treated with pembrolizumab or nivolumab, patients with PTEN-expressing tumors achieved significantly greater reduction of tumor size than those with reduction or loss of PTEN expression[126]. In a retrospective analysis of 66 patients with glioblastoma, tumors from nivolumab or pembrolizumab non-responders were significantly enriched for PTEN mutations[26]. In a patient with uterine leiomyosarcoma treated with pembrolizumab monotherapy, a treatment-resistant tumor arose that harbored PTEN loss[125].

FREQUENCY & PROGNOSIS

Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma[127-134]. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed[135]. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases[65], while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases[64]. Decreased PTEN expression is associated with the higher grade GBM tumors[136]. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas[131,137].

FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[109]. Alterations such as seen here may disrupt PTEN function or expression[133,138-177].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2021)[178]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[179-180]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[179,181]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[179]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
PPP2R2A

ALTERATION
rearrangement exon 8

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to directly address copy number alteration or mutations of PPP2R2A. While preclinical studies have linked PPP2R2A loss with defective HR repair and sensitivity to the PARP-1 inhibitor veliparib, the Phase 2 PROfound study reported a shorter median PFS for patients with PPP2R2A-altered prostate cancer treated with olaparib as compared to investigator's choice of abiraterone/prednisone or enzalutamide (2.7 months vs. not reached, HR = 6.61)[182-184]. Activation of PP2A with forskolin or the sphingosine analogue FTY720 has be shown to be beneficial in the context of CML and ALL[185] and is being investigated in tumors of the lung, breast, and colon[186-188]. In addition, other agents have been shown to upregulate PP2A activity in the context of various tumors[189]. However, the efficacy of these compounds in the context of PPP2R2A mutations has not yet been evaluated (PubMed, 2021).

FREQUENCY & PROGNOSIS

Somatic missense alterations of PPP2R2A are rare, occurring in 1% of cancers across all solid or hematological tumor types (COSMIC, 2021)[190]. In the TCGA datasets, PPP2R2A deletion was reported at the highest incidence in ovarian serous cystadenocarcinoma (8.2%), prostate adenocarcinoma (7.6%), non-small cell lung carcinoma (NSCLC, 5.3%), bladder urothelial carcinoma (5.6%), colorectal adenocarcinoma (4.7%), breast invasive carcinoma (4.4%), and at lesser frequencies in other cancer types (cBioPortal, 2021)[191-192]. In the literature, decreased expression of PPP2R2A has been reported in up to 40% of NSCLC[182-183,193], with downregulation also reported in other types of cancers, including breast cancer[193-194] and prostate cancer[195-196]. One study reported PPP2R2A copy number alteration (CNA, classified as either homozygous or heterozygous deletion) in 54% of patients with breast carcinoma, and it was associated with decreased overall survival (OS) compared to patients without PPP2R2A CNA[193]. Multiple studies have reported that PPP2R2A CNA in breast carcinoma is associated with ER-positive tumors[193-194]. Furthermore, concurrent PPP2R2A deletion and CCND1 overexpression may define a group of luminal-like, aggressive breast cancer that is associated with both poorer disease-free survival and decreased OS as well as a high risk of relapse[193]. In the context of prostate adenocarcinoma, a retrospective analysis reported that PPP2R2A hemizygous deletion was found in 42% of patients and was associated with shorter disease-free survival and higher tumor stage, whereas homozygous loss of PPP2R2A was less common (15%) and showed a non-significant tendency toward poorer prognosis[196].

FINDING SUMMARY

PPP2R2A is located on chromosome 8p21.2 and encodes B55alpha, a B regulatory subunit of the tumor suppressor protein phosphatase 2 (PP2A)[193]. PP2A is a serine/threonine phosphatase involved in regulation of cell growth and division and has been implicated in the negative regulation of proteins involved in DNA double-strand break repair, including ATM, CHK1/2, and gamma-H2AX[183,193,197-198]. Loss of function of PP2A has been associated with cell transformation; loss of PPP2R2A has been associated with increased ATM phosphorylation and activity of CHK2, BRCA1, and RAD51[183,199-200].

GENE
RB1

ALTERATION
loss exons 3-12

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of limited clinical data[201] and strong preclinical data[202-204], RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer. It should be noted that a trial of the Aurora kinase A inhibitor alisertib in advanced prostate cancer did not find an association between RB1 deletion and clinical benefit[205]. Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL-2 family members[206] and activation of the NOTCH pathway[207].

— Potential Resistance —

Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb[208-217].

— Nontargeted Approaches —

Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer[218-219].

FREQUENCY & PROGNOSIS

In the TCGA datasets, RB1 mutation or homozygous deletion was observed in 9% of glioblastomas[65] and 2.5% of lower grade glioma cases[64]. In one study, loss of RB1 transcript expression was observed in 10.6% of glioblastomas and occurred more frequently in the proneural subtype[220]. One study reports that mutation of RB1 is correlated with shorter survival in glioblastoma patients[221]. Several studies suggest that RB1, PTEN, and/or TP53 mutations are early events in the development of glioblastoma[222-224].

FINDING SUMMARY

RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle[219,225]. Alterations such as seen here may disrupt RB1 function or expression[226-232].

POTENTIAL GERMLINE IMPLICATIONS

Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year[233]. Germline mutations in RB1 account for approximately 40% of RB tumors[234] and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma[235-236]. In the appropriate clinical context, germline testing of RB1 is recommended.

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TERT

ALTERATION
promoter -146C>T

TRANSCRIPT ID
NM_198253

CODING SEQUENCE EFFECT
-146C>T

VARIANT ALLELE FREQUENCY (% VAF)
18.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches are under development, including immunotherapies utilizing TERT as a tumor-associated antigen, antisense oligonucleotide- or peptide-based therapies, and TERT promoter-directed cytotoxic molecules.

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[237-238], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[237-241]. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)[237,239]. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed[135]. The significance of the TERT promoter mutation as an independent prognostic indicator in patients with glioma is not clear. While TERT promoter mutations significantly associate with poor prognosis in patients with GBM, this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[237,239,242-243]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS, whereas in IDH-mutated, 1p/19q co-deleted oligodendroglioma, TERT mutations are associated with improved OS (NCCN CNS Cancers Guidelines, v5.2020). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[243].

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[244]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[245-247]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[248-250], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[248].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v5.2020). Co-occurring TERT mutation, IDH mutation, and 1p/19q co-deletion is indicative of oligodendroglioma, whereas IDH mutation in the absence of TERT mutation is suggestive of astrocytoma (NCCN CNS Cancers Guidelines, v5.2020).

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Selumetinib

Assay findings association

NF1
loss exons 1-8

AREAS OF THERAPEUTIC USE

Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma[47-50,251-255] , glioma[50-54,256] , and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors.

SUPPORTING DATA

Clinical data on the efficacy of selumetinib for the treatment of glioblastoma are limited (PubMed, Sep 2021). Selumetinib has demonstrated clinical activity in low-grade glioma. A Phase 2 study of selumetinib for patients with low-grade glioma (LGG) reported 8/25 PRs for patients with BRAF alterations and 10/25 PRs for those with NF1-associated LGG[51]; a Phase 1 study of selumetinib reported 5/25 PRs for patients with LGG[257]. A Phase 2 study of selumetinib for patients with tumors with activating alterations in the MAPK pathway evaluated 8 patients with high-grade glioma (HGG); 2 SDs and no objective responses were observed in this subset[258]. Selumetinib has demonstrated efficacy in NF1-associated neurofibroma in Phase 2 studies[48,251-252] and a Phase 1 study[47]. Phase 2 studies reported clinical responses in low-grade glioma[51,257] , melanoma[259-263] , and in lung[55,264-265] and endometrial cancer[266]. A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed[258]. Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non-small cell lung cancer (NSCLC), and CRC[267]; 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A[268]. Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus[269], docetaxel or dacarbazine[270], AKT inhibitors[271], or cixutumumab (an anti-IGF-1R antibody)[272] reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer.

Trametinib

Assay findings association

NF1
loss exons 1-8

AREAS OF THERAPEUTIC USE

Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma[47-50,251-255] , glioma[50-54,256] , and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors.

SUPPORTING DATA

Case studies of trametinib in NF1-associated low-grade glioma have reported 7 PRs, including 2 patients with pilocytic astrocytoma, 2 patients with diffuse astrocytoma, 3 patients with low-grade glioma experiencing PRs of over 6 months[50,52-53,256] . A study of four pediatric patients with BRAF mutation-positive non-operable astrocytoma reported a reduction in tumor volume in response to trametinib for the 3 optic gliomas with BRAF duplication[273-274] . A patient with pilocytic astrocytoma harboring an NFIA-RAF1 fusion that had progressed on multiple lines of prior treatment exhibited ongoing SD following treatment with trametinib[275]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[62], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[63].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1227775-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
MDM2

ALTERATION
amplification

RATIONALE
Inhibitors of the MDM2-p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.

NCT04589845

PHASE 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

TARGETS
ALK, ROS1, TRKA, TRKB, TRKC, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha

LOCATIONS: Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)

NCT03449381

PHASE 1

This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)

TARGETS
MDM2

LOCATIONS: Tokyo, Chuo-ku (Japan), Ottawa (Canada), Connecticut, New York, Tennessee, Florida

NCT03611868

PHASE 1/2

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

TARGETS
MDM2, PD-1

LOCATIONS: Brisbane (Australia), California, Arizona, Missouri, Arkansas, Pennsylvania, New York, Tennessee, Texas

NCT03158389

PHASE 1/2

NCT Neuro Master Match - N²M² (NOA-20)

TARGETS
ALK, RET, CDK4, CDK6, mTOR, MDM2, PD-L1, SMO

LOCATIONS: Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)

NCT03107780

PHASE 1

MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma

TARGETS
MDM2

LOCATIONS: California, Michigan, Pennsylvania, Massachusetts, New York, Maryland, North Carolina, Alabama

NCT03725436

PHASE 1

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

TARGETS
MDM2, MDM4

LOCATIONS: Texas

GENE
NF1

ALTERATION
loss exons 1-8

RATIONALE
On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK

LOCATIONS: Guangzhou (China)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas

NCT04185831

PHASE 2

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

TARGETS
PD-L1, MEK

LOCATIONS: Uppsala (Sweden), Gothenburg (Sweden)

ORDERED TEST # ORD-1227775-01

CLINICAL TRIALS

NCT03158389

PHASE 1/2

NCT Neuro Master Match - N²M² (NOA-20)

TARGETS
ALK, RET, CDK4, CDK6, mTOR, MDM2, PD-L1, SMO

LOCATIONS: Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)

NCT02407509

PHASE 1

Phase I Trial of RO5126766

TARGETS
RAFs, MEK, mTOR

LOCATIONS: London (United Kingdom), Sutton (United Kingdom)

NCT04800822

PHASE 1

PF-07284892 in Participants With Advanced Solid Tumors

TARGETS
SHP2, ROS1, ALK, BRAF, EGFR, MEK

LOCATIONS: California, Michigan, New York, Tennessee, Texas

NCT03217669

PHASE 1

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

TARGETS
IDO1, mTOR

LOCATIONS: Kansas

GENE
PTEN

ALTERATION
Q171* - subclonal

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04740190

PHASE 2

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT04001569

PHASE 1/2

AZD8186 and Paclitaxel in Advanced Gastric Cancer

TARGETS
PI3K-beta

LOCATIONS: Seongnam-si (Korea, Republic of)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California

NCT04715620

PHASE 2

Niraparib Combined With Radiotherapy in rGBM

TARGETS
PARP

LOCATIONS: Tianjin (China)

NCT04635631

PHASE 1

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

TARGETS
PARP

LOCATIONS: Beijing (China), Changchun (China)

ORDERED TEST # ORD-1227775-01

CLINICAL TRIALS

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04614909

PHASE NULL

Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM

TARGETS
PARP

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03994796

PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Alaska, Washington

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BAP1 S292T	***FANCA*** E559K	***JUN*** M260I	***MSH6*** H501Y
MTOR T1834_T1837del	***PDCD1LG2 (PD-L2)*** F236L	***PTPRO*** R684C	***TSC2*** S989R

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes. Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.1.1

The median exon coverage for this sample is 816x

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) pmid: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
9. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
11. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
13. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
15. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
19. Cristescu R, et al. Science (2018) pmid: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
24. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
25. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
26. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
27. Touat M, et al. Nature (2020) pmid: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
29. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
31. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
33. Johnson A, et al. Oncologist (2017) pmid: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
35. Wang L, et al. BMC Cancer (2020) pmid: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918
48. Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938
49. Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171
50. Ronsley R, et al. Cancer Med (2021) pmid: 33939292
51. Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904
52. Manoharan N, et al. J Neurooncol (2020) pmid: 32780261
53. Kondyli M, et al. J Neurooncol (2018) pmid: 30097824
54. Awada G, et al. Case Rep Oncol () pmid: 33082744
55. Middleton G, et al. Nature (2020) pmid: 32669708
56. Lim SM, et al. Oncotarget (2016) pmid: 26859683
57. Weiss B, et al. Neuro-oncology (2015) pmid: 25314964
58. Janku F, et al. Oncotarget (2014) pmid: 24931142
59. Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202
60. Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108
61. Malone CF, et al. Cancer Discov (2014) pmid: 24913553
62. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
63. Patterson et al., 2018; AACR Abstract 3891
64. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
65. Brennan CW, et al. Cell (2013) pmid: 24120142
66. Nature (2008) pmid: 18772890
67. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
68. Vizcaíno MA, et al. Hum. Pathol. (2015) pmid: 26190195
69. Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223
70. Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317
71. Ballester R, et al. Cell (1990) pmid: 2121371
72. Xu GF, et al. Cell (1990) pmid: 2116237
73. Martin GA, et al. Cell (1990) pmid: 2121370
74. Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134
75. Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663
76. Messiaen LM, et al. Genet. Med. () pmid: 11258625
77. Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834
78. Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657
79. Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648
80. Jett K, et al. Genet. Med. (2010) pmid: 20027112
81. Patil S, et al. Oncologist (2012) pmid: 22240541
82. Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231
83. Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190
84. Williams VC, et al. Pediatrics (2009) pmid: 19117870
85. Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744
86. Ohnstad HO, et al. Cancer (2013) pmid: 23165797
87. Gamble LD, et al. Oncogene (2012) pmid: 21725357
88. Zhang et al., 2019; ASCO Abstract 3124
89. Rasco et al., 2019; ASCO Abstract 3126
90. Tolcher et al., 2021; ASCO Abstract 2506
91. Martinelli et al., 2016; EHA21 Abstract S504
92. Daver et al., 2018; ASH Abstract 767
93. Mascarenhas et al., 2019; ASH Abstract 134
94. Shustov et al., 2018; ASH Abstract 1623
95. Sallman et al., 2018; ASH Abstract 4066
96. Meric-Bernstam et al., 2017; ASCO Abstract 2505
97. Zheng S, et al. Genes Dev. (2013) pmid: 23796897
98. Fischer U, et al. Int. J. Cancer (2010) pmid: 19839052
99. Sdek P, et al. Mol. Cell (2005) pmid: 16337594
100. Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057
101. Li M, et al. Mol. Cell (2004) pmid: 15053880
102. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
103. Cordon-Cardo C, et al. Cancer Res. (1994) pmid: 8306343
104. Beroukhim R, et al. Nature (2010) pmid: 20164920
105. Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930
106. Singavi et al., 2017; ESMO Abstract 1140PD
107. Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640
108. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
109. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
110. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
111. Milella M, et al. Sci Rep (2017) pmid: 28220839
112. Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902
113. Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475
114. Mason WP, et al. Invest New Drugs (2012) pmid: 22160854
115. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
116. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
117. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
118. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
119. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
120. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
121. Dougherty et al., 2014; ASCO Abstract 5536
122. Pan M, et al. Perm J (2021) pmid: 33970096
123. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
124. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
125. George S, et al. Immunity (2017) pmid: 28228279
126. Peng W, et al. Cancer Discov (2016) pmid: 26645196
127. Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247
128. Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072
129. Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904
130. Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770
131. Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977
132. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660
133. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241
134. Furnari FB, et al. Genes Dev. (2007) pmid: 17974913
135. Yan et al. 2020; DOI:10.1200/PO.19.00385
136. Sano T, et al. Cancer Res. (1999) pmid: 10213484
137. Srividya MR, et al. Neuropathology (2011) pmid: 21134002
138. Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747
139. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076
140. He X, et al. Cancer Res. (2013) pmid: 23475934
141. Han SY, et al. Cancer Res. (2000) pmid: 10866302
142. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831
143. Pradella LM, et al. BMC Cancer (2014) pmid: 24498881
144. Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651
145. Denning G, et al. Oncogene (2007) pmid: 17213812
146. Hlobilkova A, et al. Anticancer Res. () pmid: 16619501
147. Redfern RE, et al. Protein Sci. (2010) pmid: 20718038
148. Shenoy S, et al. PLoS ONE (2012) pmid: 22505997
149. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485
150. Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519
151. Lee JO, et al. Cell (1999) pmid: 10555148
152. Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567
153. Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913
154. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

155. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
156. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
157. Liu J, et al. Oncogene (2014) pmid: 23995781
158. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
159. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691
160. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
161. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
162. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
163. Gil A, et al. PLoS ONE (2015) pmid: 25875300
164. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
165. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
166. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
167. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
168. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
169. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
170. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
171. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
172. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
173. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
174. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
175. Wang X, et al. Biochem. J. (2008) pmid: 18498243
176. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
177. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
178. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
179. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
180. Orloff MS, et al. Oncogene (2008) pmid: 18794875
181. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
182. Kalev P, et al. Cancer Res. (2012) pmid: 23087057
183. Wang YQ, et al. J. Med. Chem. (2016) pmid: 27416328
184. de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890
185. Perrotti D, et al. Lancet Oncol. (2013) pmid: 23639323
186. Cristóbal I, et al. Mol. Cancer Ther. (2014) pmid: 24448818
187. Saddoughi SA, et al. EMBO Mol Med (2013) pmid: 23180565
188. Baldacchino S, et al. EPMA J (2014) pmid: 24460909
189. Chen W, et al. Gastroenterol Res Pract (2013) pmid: 24307892
190. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
191. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
192. Gao J, et al. Sci Signal (2013) pmid: 23550210
193. Beca F, et al. BMC Cancer (2015) pmid: 25879784
194. Curtis C, et al. Nature (2012) pmid: 22522925
195. Mao X, et al. Am J Cancer Res (2011) pmid: 21994901
196. Zhao Z, et al. Oncogenesis (2019) pmid: 31822657
197. Freeman AK, et al. Cell Commun. Signal (2010) pmid: 20860841
198. Wurzenberger C, et al. Nat. Rev. Mol. Cell Biol. (2011) pmid: 21750572
199. Westermarck J, et al. Trends Mol Med (2008) pmid: 18329957
200. Eichhorn PJ, et al. Biochim. Biophys. Acta (2009) pmid: 18588945
201. Owonikoko et al., 2016; ESMO Abstract 14230
202. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
203. Gong X, et al. Cancer Discov (2019) pmid: 30373917
204. Oser MG, et al. Cancer Discov (2019) pmid: 30373918
205. Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224
206. Allaman-Pillet N, et al. Ophthalmic Genet. () pmid: 21955141
207. Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955
208. Condorelli R, et al. Ann. Oncol. (2018) pmid: 29236940
209. Fry DW, et al. Mol. Cancer Ther. (2004) pmid: 15542782
210. Dean JL, et al. Oncogene (2010) pmid: 20473330
211. Dean JL, et al. Cell Cycle (2012) pmid: 22767154
212. Garnett MJ, et al. Nature (2012) pmid: 22460902
213. Roberts PJ, et al. J. Natl. Cancer Inst. (2012) pmid: 22302033
214. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
215. O'Leary B, et al. Cancer Discov (2018) pmid: 30206110
216. Costa C, et al. Cancer Discov (2019) pmid: 31594766
217. Chen SH, et al. Oncogene (2018) pmid: 29059158
218. Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962
219. Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056
220. Goldhoff P, et al. J. Neuropathol. Exp. Neurol. (2012) pmid: 22157621
221. Bäcklund LM, et al. Clin. Cancer Res. (2003) pmid: 14519639
222. Chow LM, et al. Cancer Cell (2011) pmid: 21397855
223. Nobusawa S, et al. Brain Pathol. (2010) pmid: 20406234
224. Deighton RF, et al. Brain Pathol. (2010) pmid: 20175778
225. Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841
226. Berge EO, et al. Mol. Cancer (2010) pmid: 20594292
227. Giacinti C, et al. Oncogene (2006) pmid: 16936740
228. Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358
229. Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322
230. Qin XQ, et al. Genes Dev. (1992) pmid: 1534305
231. Rubin SM, et al. Cell (2005) pmid: 16360038
232. Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662
233. Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159
234. Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621
235. Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478
236. Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033
237. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
238. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
239. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
240. Liu X, et al. Cell Cycle (2013) pmid: 23603989
241. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
242. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
243. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
244. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
245. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
246. Kim NW, et al. Science (1994) pmid: 7605428
247. Hanahan D, et al. Cell (2000) pmid: 10647931
248. Horn S, et al. Science (2013) pmid: 23348503
249. Huang FW, et al. Science (2013) pmid: 23348506
250. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
251. Glassberg et al., 2020; ASPHO Abstract 2015
252. Coyne et al., 2020; ASCO Abstract 3612
253. McCowage et al., 2018; ASCO Abstract 10504
254. Mueller et al., 2020; SNO Abstract NFB-17
255. Waldner et al., 2020; DOI: 10.1055/s-0040-1715638
256. Romo et al., 2019; SNO Abstract RARE-54
257. Banerjee A, et al. Neuro-oncology (2017) pmid: 28339824
258. Allen et al., 2021; ASCO Abstract 10008
259. Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366
260. Robert C, et al. Lancet Oncol. (2013) pmid: 23735514
261. Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237
262. Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232
263. Boers-Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660
264. Lopez-Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274
265. Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351
266. Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099
267. Deming DA, et al. Invest New Drugs (2016) pmid: 26666244
268. Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150
269. Infante JR, et al. Invest New Drugs (2017) pmid: 28424891
270. LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648
271. Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890
272. Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371
273. Miller et al., 2016; ISPNO Abstract LG-01
274. Miller C, et al. J Neurosurg Pediatr (2017) pmid: 28009226
275. Yde CW, et al. Cancer Genet (2016) pmid: 27810072

Electronically signed by Erik Williams, M.D. | 10 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531